New US FDA Powers On Rx Abuse Could Be 'Tailored' By Congress, Gottlieb Suggests
Executive Summary
At House hearing on opioid epidemic, FDA Commissioner responds to range of legislative proposals, including those aimed at agency's drug approval and safety monitoring activities.
You may also be interested in...
Over-Legislating On Opioids? US FDA May Get New Authorities And Unwanted Tasks
In the face of the overwhelming opioid abuse epidemic, it is hard to argue against doing more. But, at least when it comes to some of the FDA-related bills pending, there is a good argument that Congress is in danger of over-legislating.
CMS Wants Broader Use of Abuse-Deterrent Opioids – But Needs Help From Congress
Abuse-deterrent formulations are 'potentially useful tool,' but CMS believe it lacks authority to mandate favorable coverage in Part D plans. House E&C committee has nearly three dozen Medicare & Medicaid proposals under consideration – but none that specifically gives CMS the authority it says it needs.
Senate Draft Bill On Opioids Tasks US FDA With Clarifying Its Regulation Of New Treatments
Discussion draft released by Senate HELP Committee directs agency to hold at least one public meeting and issue four guidances on a range of issues.